By Sherri Oslick --
About Court Report: Each week we will report briefly
on recently filed biotech and pharma patent cases. A few interesting cases will be selected for
periodic monitoring, providing our readers with an opportunity to follow the
progress of these cases.
Novartis Corp. et. a. v. Lupin Ltd. et al.
1:06-cv-03338; filed December 14, 2006 in the District
Court of Maryland
Infringement of U.S. Patent No. 6,162,802
("Synergistic Combination Therapy Using Benazepril and Amlodipine for the
Treatment of Cardiovascular Disorders and Compositions Therefor," issued
December 19, 2000) following a paragraph IV certification as part of Lupin's
filing of an ANDA to manufacture a generic version of Novartis' Lotrel®
(amlodipine besylate/benazepril hydrochloride, used to treat
hypertension). View the complaint here.
NexMed Holdings, Inc. v. Beta Technologies, Inc. et. al.
2:06-cv-01014; filed December 8, 2006 in the District
Court of Utah
Infringement of U.S. Patent Nos. 5,133,352 ("Method for Treating Herpes Simplex," issued July 28, 1992) and 6,083,250 ("Apparatus and Method for Inhibiting Lesion Formation by Selectively Treating the Prodromal Stage of the Lesion with a Pulsatile Electrical Stimulation," issued July 4, 2000) based on Beta Technologies' marketing and sale of "Cold Sore Inhibitor," an apparatus for performing a method of treating herpes simplex. View the complaint here.
Comments